查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014291

計算生物學市場：按產品類型、技術、應用和最終用戶分類 - 2026-2032年全球市場預測

Computational Biology Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，計算生物學市場價值將達到 88.3 億美元，到 2026 年將成長到 105 億美元，到 2032 年將達到 307.8 億美元，年複合成長率為 19.52%。

主要市場統計數據
基準年 2025 88.3億美元
預計年份：2026年 105億美元
預測年份 2032 307.8億美元
複合年成長率 (%) 19.52%

本文簡要概述了計算生物學領域在創新、整合和策略重點方面的需求，供研究、臨床和商業領域的決策者參考。

本執行摘要首先概述了計算生物學的現狀，並闡述了其為何值得科研、臨床實踐和商業應用領域的領導者關注。其目的是闡明關鍵的技術進步領域、濕實驗室和乾實驗室能力之間不斷演變的互動關係，以及專注於藥物發現、診斷和治療方法開發的相關人員所面臨的戰略選擇。重點在於分析通量、數據整合和下游決策的顯著變化，這些變化共同重塑了營運重點。

資料規模化、組體學、自動化和雲端原生分析正在重塑運算生物學，帶來重大變革。

計算生物學領域正經歷一系列變革，這主要得益於儀器、分析技術和計算資源的協同進步。高通量定序和成像平台產生的資料規模龐大，對儲存、運算和可重複分析提出了新的要求。同時，機器學習和雲端原生架構使得發現更複雜的模式和進行預測建模成為可能，加速了假設的生成和轉換應用。因此，各組織機構正從臨時資料處理轉向專用資料平台和管治框架，以支援跨職能研究和標準化使用。

美國關稅調整對計算生物學供應鏈的採購、供應商策略和營運韌性的影響。

2025年美國關稅政策調整的累積影響，為整個計算生物學生態系統的採購、供應鏈韌性和全球採購策略帶來了新的考量。關稅調整往往會增加某些類別進口設備、試劑及相關硬體組件的到貨成本，迫使各機構重新評估供應商選擇標準和總體擁有成本（TCO）。這促使採購團隊更細緻地觀點供應商所在地、物流安排和緊急儲備措施，並將其納入日常風險緩解措施。

將產品類型、底層技術、應用和不同的最終用戶聯繫起來的全面細分洞察，揭示了差異化的需求趨勢。

細分市場分析揭示了微妙的需求模式，有助於確定該行業產品和服務的優先順序。根據產品類型，儀器、試劑和耗材以及軟體和服務各自構成不同的價值類別。儀器包括先進的成像系統、質譜平台、微陣列掃描儀、PCR平台和高通量定序儀，每種儀器都有其獨特的資本投入和營運規模。試劑和耗材包括樣品製備試劑、PCR試劑、蛋白質體學試劑和定序試劑，這些都需要定期購買並考慮低溫運輸運輸。軟體和服務包括生物資訊服務、數據分析軟體和儀器維護服務，這些服務直接支援物理資產的分析能力。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略意義影響著採用、採購和夥伴關係關係。

區域趨勢影響著美洲、歐洲、中東、非洲以及全部區域的戰略重點和投資模式。在美洲，成熟的研究機構、成熟的生物技術產業以及活躍的臨床試驗活動，持續推動對先進儀器、專用試劑和整合軟體解決方案的需求。此外，該地區重視臨床應用方面的監管清晰度，並受益於某些高價值儀器的強大國內生產能力，這增強了採購的韌性。

一項策略競爭考察揭示了整合解決方案、在地化服務和合作夥伴關係如何決定計算生物學領域領導者的成敗。

對競爭考察和主要企業能力的洞察反映出，在當前市場環境中，創新、服務生態系統和策略夥伴關係是關鍵的差異化因素。投資於整合強大儀器、檢驗的試劑和先進分析能力的端到端解決方案的企業，往往能為大型企業客戶提供更具吸引力的價值提案。同時，專注於利基技術和高性能試劑的專業供應商也發揮著至關重要的作用，他們提供實現複雜工作流程所需的組件。此外，協作結構、分銷網路和在地化服務能力也進一步影響企業如何將技術優勢轉化為持久的客戶關係。

為產業領導者提供切實可行的建議，以加強採購韌性、資料管治、人才能力和監管合規性，從而確保永續的競爭優勢。

產業和研究領導者應優先考慮一系列切實可行的舉措，以增強韌性並從持續的技術變革中創造價值。首先，將籌資策略與設備的長期生命週期規劃和全面的服務合約結合，可以降低短期成本波動帶來的風險，並支援可預測的營運。各機構應協商簽訂包含耗材保固、預防性保養計劃和技術升級選項的多年期契約，使資本投資週期與科研需求相匹配。

採用嚴謹的混合方法調查方法，結合專家的直接訪談、第二手資料的整合、情境分析和多階段檢驗過程。

本調查方法透過結合一手質性資料、嚴謹的二手資料整合和迭代檢驗，確保分析的一致性。一手資料包括與領域專家、採購專家、研究機構負責人和技術服務經理進行結構化訪談和諮詢，以了解實際營運中的限制因素和技術採納促進因素。這些訪談內容被整合起來，用於識別反覆出現的主題，並對有關技術採納、供應鏈脆弱性和服務模式有效性的假設進行壓力測試。

摘要重點闡述了技術採用、資料管治、供應商韌性和人才發展之間的策略協調，以實現轉換影響。

總之，計算生物學正處於一個關鍵的十字路口，技術進步、資料規模和營運複雜性正在重新定義發現的方式以及實用化的方式。先進的定序和成像平台、高維蛋白質組學以及可擴展的分析框架的融合，能夠帶來更豐富的生物學洞見，但同時，也增加了對穩健的數據管治、供應商韌性和有針對性的人才培養的需求。那些積極調整籌資策略、投資可互通的數據基礎設施並建立戰略供應商關係的組織，將更有能力將技術潛力轉化為可重複的科學和臨床成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 計算生物學市場：依產品類型分類

  • 裝置
    • 影像系統
    • 質譜儀
    • 微陣列掃描儀
    • PCR裝置
    • 定序裝置
  • 試劑和耗材
  • 軟體服務
    • 生物資訊服務
    • 數據分析軟體
    • 設備維護服務

第9章 計算生物學市場：依技術分類

  • 影像系統
    • 共聚焦顯微鏡
    • 電子顯微鏡
    • 螢光影像
  • 微陣列
    • DNA微陣列
    • 蛋白質微陣列
  • 質譜分析
  • 次世代定序
    • Illumina定序
    • 離子流定序

第10章 計算生物學市場：依應用領域分類

  • 診斷
    • 癌症診斷
    • 基因檢測
    • 感染疾病
  • 藥物發現
    • 先導藥物最適化
    • 目標識別
    • 毒性篩檢
  • 基因組分析
    • DNA定序
    • 表觀遺傳分析
    • RNA定序
  • 蛋白質體學分析
    • 蛋白質鑑定
    • PTM 分析
    • 定量蛋白質體學

第11章 計算生物學市場：依最終使用者分類

  • 學術和研究機構
    • 政府附屬研究機構
    • 大學
  • 合約研究機構
    • 主要CRO
    • 利基CRO
  • 醫院和診斷檢查室
    • 醫院檢查室
    • 獨立診斷檢測實驗室
  • 製藥和生物技術公司
    • 生技公司
    • 製藥公司

第12章 計算生物學市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 計算生物學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 計算生物學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國計算生物學市場

第16章 中國計算生物學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Group
  • Biomax Informatics AG
  • Chemical Computing Group Inc.
  • Compugen Ltd.
  • Dassault Systemes SE
  • DNAnexus, Inc.
  • DNASTAR, Inc.
  • Eurofins Scientific SE
  • Genedata AG
  • Illumina, Inc.
  • Insilico Medicine
  • Instem Group
  • Nimbus Discovery Llc
  • PerkinElmer, Inc.
  • ProFound Therapeutics
  • QIAGEN NV
  • Rosa & Co. Llc
  • Schrodinger, Inc.
  • Simulation Plus Inc.
  • SOPHiA GENETICS
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
  • WuXi NextCODE
Product Code: MRR-433AB1DC289D

The Computational Biology Market was valued at USD 8.83 billion in 2025 and is projected to grow to USD 10.50 billion in 2026, with a CAGR of 19.52%, reaching USD 30.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.83 billion
Estimated Year [2026] USD 10.50 billion
Forecast Year [2032] USD 30.78 billion
CAGR (%) 19.52%

Concise orientation to computational biology innovations, integration imperatives, and strategic priorities for research, clinical, and commercial decision-makers

This executive summary opens with a focused orientation to the computational biology landscape and why it demands attention from leaders across research, clinical, and commercial settings. The intent is to clarify the principal domains of technological advancement, the evolving interplay between wet-lab and dry-lab capabilities, and the strategic choices facing stakeholders invested in discovery, diagnostics, and therapeutic development. Emphasis is placed on demonstrable shifts in analytical throughput, data integration, and downstream decision-making that together reshape operational priorities.

Importantly, this introduction outlines the analytical approach that underpins subsequent insights: synthesizing technological trajectories, regulatory considerations, and supply-chain dynamics to form a coherent narrative for planning and investment. It also frames the report's utility for multiple audiences, including research directors, procurement leads, and business strategists, by describing the types of actionable outputs they can expect. Finally, this section situates the following analysis within the broader context of accelerating data volumes and computational complexity, setting the stage for targeted recommendations and operational responses.

Key transformative shifts reshaping computational biology driven by data scale expansion, integrative omics, automation, and cloud-native analytics

The landscape of computational biology is undergoing a series of transformative shifts driven by synergistic advances in instrumentation, analytical methods, and computational resources. High-throughput sequencing and imaging platforms are producing data at scales that require new paradigms in storage, compute, and reproducible analysis. Concurrently, machine learning and cloud-native architectures are enabling more complex pattern discovery and predictive modeling, which in turn accelerate hypothesis generation and translational applications. As a result, organizations are moving from ad hoc data handling toward purpose-built data platforms and governance frameworks that support cross-functional research and regulated use.

Another critical shift is the maturation of integrative omics and multimodal analysis, where genomic, transcriptomic, proteomic, and imaging data are combined to deliver richer biological context. This integration is driving demand for interoperable software and standardized pipelines that reduce friction between instrument outputs and downstream analytics. In parallel, automation and robotic workflows are reducing manual variability while improving reproducibility in wet-lab processes, permitting a re-allocation of scientific talent toward higher-value tasks. Finally, collaborative models between academia, industry, and service providers are expanding; these partnerships are increasingly structured around data-sharing agreements, IP governance, and joint development efforts, which require sophisticated contractual and operational arrangements to realize long-term value.

Implications of U.S. tariff adjustments on procurement, supplier strategies, and operational resilience across computational biology supply chains

The cumulative influence of United States tariff policy changes in 2025 has introduced renewed considerations for procurement, supply chain resilience, and global sourcing strategies across the computational biology ecosystem. Tariff adjustments have tended to increase landed costs for certain categories of imported instrumentation, reagents, and associated hardware components, prompting organizations to reassess vendor selection criteria and total cost of ownership. This has led procurement teams to adopt a more granular view of supplier footprints, logistics timelines, and contingency stock practices as part of routine risk mitigation.

Moreover, tariff-driven cost pressures have encouraged local sourcing where feasible, spurring greater dialogue between manufacturers and regional distributors about contract flexibility and tiered pricing arrangements. For research and clinical operations, these dynamics have sometimes delayed equipment upgrades or reagent adoption when budget cycles could not absorb sudden increases in procurement expense, thereby affecting project timelines. At the same time, tariffs have catalyzed negotiation behaviors that prioritize multi-year service agreements, bundled consumables contracts, and collaborative forecasting to secure more predictable supply. From a strategic perspective, organizations are balancing immediate operational adjustments with longer-term supplier development and on-shoring considerations to stabilize access to critical instruments and consumables.

Comprehensive segmentation insights linking product types, enabling technologies, applications, and diverse end users to reveal differentiated demand dynamics

Segmentation analysis reveals nuanced demand patterns that inform product and service prioritization across the field. Based on product type, instruments, reagents and consumables, and software and services operate as distinct value categories. Instruments encompass advanced imaging systems, mass spectrometry platforms, microarray scanners, PCR platforms, and high-throughput sequencing equipment, each with specific capital and operational footprints. Reagents and consumables span library preparation reagents, PCR reagents, proteomics reagents, and sequencing reagents, which carry recurring procurement lifecycles and cold-chain sensitivities. Software and services include bioinformatics services, data analysis software, and instrument maintenance services that directly enable the analytical utility of physical assets.

When viewed through the lens of technology, demand concentrates around imaging modalities, mass spectrometry techniques, microarray methodologies, next-generation sequencing approaches, and polymerase chain reaction variants. Imaging subdivides into confocal, electron, and fluorescence imaging, each serving different resolution and throughput needs; mass spectrometry differentiates between ESI-MS and MALDI-TOF workflows; microarray offerings include DNA and protein microarrays; next-generation sequencing encompasses Illumina-style short-read, semiconductor-based platforms, and long-read nanopore technologies; and PCR differentiates digital PCR and quantitative PCR methods.

Application-oriented segmentation clarifies end-use drivers, with diagnostics, drug discovery, genomic analysis, and proteomic analysis representing core demand streams. Diagnostics includes cancer diagnostics, genetic testing, and infectious disease detection that demand regulatory rigor and clinical validation. Drug discovery covers lead optimization, target identification, and toxicity screening where throughput and assay robustness are paramount. Genomic analysis spans DNA sequencing, epigenetic profiling, and RNA sequencing, while proteomic analysis focuses on protein identification, post-translational modification characterization, and quantitative proteomics workflows.

End-user segmentation highlights the distribution of consumption across academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies. Academic and research institutes include government research centers and universities that often prioritize methodological flexibility and collaboration. Contract research organizations range from large multinational CROs to niche specialist firms that offer scale and specialized expertise. Hospitals and diagnostic laboratories differentiate between hospital-based laboratories and independent diagnostic centers that balance throughput with regulatory compliance. Pharmaceutical and biotechnology organizations encompass both biotech innovators and established pharmaceutical companies focused on pipeline advancement and clinical translation.

Regional dynamics and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, procurement, and partnerships

Regional dynamics are shaping strategic priorities and investment patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, established research institutions, a mature biotech sector, and dense clinical trial activity create sustained demand for advanced instruments, specialized reagents, and integrated software solutions. This region also emphasizes regulatory clarity for clinical applications and benefits from robust domestic manufacturing capacity for certain high-value instruments, which supports procurement resilience.

Europe, the Middle East & Africa presents a heterogeneous landscape in which advanced research hubs coexist with emerging centers of excellence. Regulatory frameworks and reimbursement environments vary considerably, requiring localized strategies for clinical validation and commercialization. Partnerships between academic consortia and industrial sponsors are common, and there is strong interest in interoperability standards and data-sharing frameworks that facilitate cross-border collaborative science. Infrastructure investments and regional funding initiatives are influencing adoption curves in targeted therapeutic and diagnostic areas.

Asia-Pacific is characterized by rapid capacity expansion, increasing clinical research activity, and growing local manufacturing capability. This region demonstrates accelerated uptake of sequencing, PCR, and imaging platforms driven by large population cohorts, strategic national initiatives in genomics, and partnerships with global suppliers. Procurement decisions in Asia-Pacific often emphasize cost-efficiency, scalability, and supplier responsiveness, leading to diversified sourcing strategies and demand for localized support and service models. Taken together, these regional patterns require vendors and research partners to craft differentiated value propositions that reflect local regulatory, economic, and operational realities.

Strategic competitive insights revealing how integrated solutions, localized services, and collaborative partnerships determine leadership outcomes in computational biology

Competitive and capability insights among leading companies reflect a landscape where innovation, service ecosystems, and strategic partnerships are primary differentiators. Organizations that invest in end-to-end solutions-integrating robust instrumentation with validated reagents and advanced analytics-tend to deliver more compelling value propositions for enterprise-scale customers. At the same time, specialist providers that focus on niche technologies or high-performance reagents maintain critical roles by supplying enabling components for complex workflows. Collaborative arrangements, distribution networks, and localized service capabilities further influence how companies convert technological advantages into lasting customer relationships.

Price and total-cost dynamics influence procurement decisions, but sustained differentiation often arises from service quality, regulatory support, and the ability to offer validated workflows for clinical and translational use cases. Strategic behaviors observed include increased licensing of analytical software to complement instrument sales, expanded field service and maintenance offerings to protect uptime, and investment in generative AI-assisted tools to accelerate data interpretation. In addition, companies are pursuing partnerships with academic consortia and contract research organizations to co-develop standards and accelerate adoption in regulated environments. Overall, the competitive environment rewards nimble firms that balance deep technical expertise with scalable commercialization and service models.

Actionable recommendations for industry leaders to strengthen procurement resilience, data governance, workforce capabilities, and regulatory engagement for sustained advantage

Leaders across industry and research should prioritize a set of pragmatic actions to build resilience and capture value from ongoing technological transitions. First, aligning procurement strategies with long-term instrument lifecycle planning and bundled service agreements will reduce exposure to short-term cost volatility and support predictable operations. Organizations should negotiate multi-year support arrangements that include consumable guarantees, preventative maintenance schedules, and options for technology refreshes to align capital investment cycles with scientific needs.

Second, investing in data infrastructure and governance is essential. Establishing scalable storage, reproducible pipelines, and clear data stewardship protocols will accelerate time-to-insight and reduce downstream rework. This includes adopting containerized workflows and standardized metadata practices that improve interoperability across instruments and analysis platforms. Third, cultivate supplier diversification while developing strategic local partnerships to reduce single-source dependencies and improve access to critical reagents and spare parts. Fourth, prioritize workforce development by expanding training in bioinformatics, data science, and laboratory automation to ensure teams can fully leverage integrated platforms. Finally, engage proactively with regulatory and reimbursement stakeholders to design validation strategies that facilitate clinical translation and reduce commercialization friction, using pilot studies and real-world evidence collection as demonstrable proof points.

Rigorous mixed-methods research methodology combining primary expert consultations, secondary evidence synthesis, scenario analysis, and multi-stage validation processes

The research methodology blends primary qualitative inputs with rigorous secondary synthesis and iterative validation to ensure analytical integrity. Primary inputs included structured interviews and consultations with domain experts, procurement specialists, laboratory directors, and technical service leads to capture real-world operational constraints and adoption drivers. These conversations were synthesized to identify recurring themes and to stress-test assumptions regarding technology adoption, supply chain sensitivity, and service model efficacy.

Secondary sources encompassed peer-reviewed literature, standards and regulatory guidance documents, technical white papers, and vendor documentation to construct a robust evidentiary base. Findings were triangulated through cross-referencing of independent sources and reconciled against expert testimony to minimize bias and ensure reproducibility. Finally, the methodology incorporated scenario-based analysis to examine risk exposures such as tariff shifts, supply disruptions, and rapid technological obsolescence. Quality controls included peer review by subject-matter experts and sensitivity checks to validate interpretive conclusions and to ensure the final outputs are actionable for decision-makers.

Concluding synthesis emphasizing strategic alignment of technology adoption, data governance, supplier resilience, and workforce development for translational impact

In conclusion, computational biology stands at a pivotal juncture where technological progress, data scale, and operational complexity are redefining how discoveries are made and translated. The confluence of advanced sequencing and imaging platforms, high-dimensional proteomics, and scalable analytical frameworks is enabling richer biological insight, but it also raises imperatives for robust data governance, supplier resilience, and targeted workforce development. Organizations that proactively adapt procurement strategies, invest in interoperable data infrastructure, and cultivate strategic supplier relationships will be better positioned to translate technological potential into reproducible scientific and clinical outcomes.

Looking forward, success will depend on pragmatic orchestration: aligning technology acquisition with end-user competencies, ensuring regulatory readiness for clinical applications, and building agile partnerships that bridge innovation and operational continuity. By focusing on these priorities, stakeholders can reduce transition friction, accelerate translational timelines, and create durable competitive advantages in an increasingly data-driven life sciences environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Computational Biology Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Imaging Systems
    • 8.1.2. Mass Spectrometry Instruments
    • 8.1.3. Microarray Scanners
    • 8.1.4. PCR Instruments
    • 8.1.5. Sequencing Instruments
  • 8.2. Reagents & Consumables
  • 8.3. Software & Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Data Analysis Software
    • 8.3.3. Instrument Maintenance Services

9. Computational Biology Market, by Technology

  • 9.1. Imaging Systems
    • 9.1.1. Confocal Microscopy
    • 9.1.2. Electron Microscopy
    • 9.1.3. Fluorescence Imaging
  • 9.2. Microarray
    • 9.2.1. DNA Microarray
    • 9.2.2. Protein Microarray
  • 9.3. Mass Spectrometry
  • 9.4. Next Gen Sequencing
    • 9.4.1. Illumina Sequencing
    • 9.4.2. Ion Torrent Sequencing

10. Computational Biology Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Cancer Diagnostics
    • 10.1.2. Genetic Testing
    • 10.1.3. Infectious Disease
  • 10.2. Drug Discovery
    • 10.2.1. Lead Optimization
    • 10.2.2. Target Identification
    • 10.2.3. Toxicity Screening
  • 10.3. Genomic Analysis
    • 10.3.1. DNA Sequencing
    • 10.3.2. Epigenetic Analysis
    • 10.3.3. RNA Sequencing
  • 10.4. Proteomic Analysis
    • 10.4.1. Protein Identification
    • 10.4.2. PTM Analysis
    • 10.4.3. Quantitative Proteomics

11. Computational Biology Market, by End User

  • 11.1. Academic & Research Institutes
    • 11.1.1. Government Research Centers
    • 11.1.2. Universities
  • 11.2. Contract Research Organizations
    • 11.2.1. Large CROs
    • 11.2.2. Niche CROs
  • 11.3. Hospitals & Diagnostic Laboratories
    • 11.3.1. Hospital Laboratories
    • 11.3.2. Independent Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies
    • 11.4.1. Biotechnology Companies
    • 11.4.2. Pharmaceutical Companies

12. Computational Biology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Computational Biology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Computational Biology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Computational Biology Market

16. China Computational Biology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. BGI Group
  • 17.7. Biomax Informatics AG
  • 17.8. Chemical Computing Group Inc.
  • 17.9. Compugen Ltd.
  • 17.10. Dassault Systemes SE
  • 17.11. DNAnexus, Inc.
  • 17.12. DNASTAR, Inc.
  • 17.13. Eurofins Scientific SE
  • 17.14. Genedata AG
  • 17.15. Illumina, Inc.
  • 17.16. Insilico Medicine
  • 17.17. Instem Group
  • 17.18. Nimbus Discovery Llc
  • 17.19. PerkinElmer, Inc.
  • 17.20. ProFound Therapeutics
  • 17.21. QIAGEN N.V.
  • 17.22. Rosa & Co. Llc
  • 17.23. Schrodinger, Inc.
  • 17.24. Simulation Plus Inc.
  • 17.25. SOPHiA GENETICS
  • 17.26. Thermo Fisher Scientific Inc.
  • 17.27. Waters Corporation
  • 17.28. WuXi NextCODE

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPUTATIONAL BIOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPUTATIONAL BIOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPUTATIONAL BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPUTATIONAL BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MASS SPECTROMETRY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MASS SPECTROMETRY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MASS SPECTROMETRY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY SEQUENCING INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY SEQUENCING INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY SEQUENCING INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENT MAINTENANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENT MAINTENANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENT MAINTENANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONFOCAL MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONFOCAL MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONFOCAL MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ELECTRON MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ELECTRON MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ELECTRON MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY FLUORESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY FLUORESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY FLUORESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DNA MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DNA MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DNA MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEIN MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEIN MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEIN MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CANCER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CANCER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CANCER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY TOXICITY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY TOXICITY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY TOXICITY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY EPIGENETIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEIN IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEIN IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEIN IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PTM ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PTM ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PTM ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY QUANTITATIVE PROTEOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY QUANTITATIVE PROTEOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY QUANTITATIVE PROTEOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY LARGE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY LARGE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY LARGE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY NICHE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY NICHE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY NICHE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL COMPUTATIONAL BIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY NEXT GEN SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY GENOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA COMPUTATIONAL BIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, BY